New England Journal of Medicine· 2013Q1· Clinical trial
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
- 1,869citations
- Q1SCImago
- 2013year
Short summary
Once-daily edoxaban, an oral factor Xa inhibitor, proved non-inferior to warfarin for treating venous thromboembolism and significantly reduced bleeding events.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Internal Medicine
Internal MedicineMedicine